Showing posts with label Vanguard. Show all posts

Wednesday, July 23, 2025

Why do Nvidia and so many institutional investors own most of the shares of RXRX - Recursion Pharma

Why Nvidia Invested in RXRX

1. Deep AI Integration for Drug Discovery

In July 2023, Nvidia invested $50 million via a PIPE deal to help Recursion accelerate training of AI models for drug discovery. This investment boosted RXRX stock by about 83% immediately Reuters
Nvidia provided cutting-edge GPUs and access to its BioNeMo generative-AI cloud platform so Recursion could train models on its massive biological dataset MarketWatch+2.

2. Equity Stake & Strategic Synergy

Nvidia now holds over 7.7 million shares—approximately a 3–4% stake—making Recursion one of its top non-core holdings The Times+11
This aligns with Nvidia’s broader strategy of investing in AI-first companies that complement its hardware, not just selling chips.

3. Accelrating RXRX’s Supercomputer Ambitions

Recursion built BioHive‑2, a supercomputer powered by Nvidia’s DGX H100 GPUs. It delivers a 4x speed increase over their prior system, enabling faster model training Reuters+2T
This partnership helps validate Nvidia hardware in high-performance biotech applications—which can drive future sales to pharma partners.

🏥 Broader Vision: Redefining Pharma with AI

Recursion uses AI, automation, and robotics to develop drugs more quickly and affordably. Its platform includes the “virtual cell” paradigm and is backed by major pharma companies like Bayer and Roche Investors+14.
Analysts project RXRX revenue growing at a ~65–73% CAGR through 2027—significantly above typical biotech growth—with Nvidia’s backing lending extra credibility The Motley Fool+5

✅ Summary

Nvidia's investment in RXRX is twofold:

Financial Buy-In – it gains exposure to a high-growth biotech using AI and fosters long-term capital appreciation.
Strategic Alignment – Nvidia deepens integration of its AI stack (hardware + BioNeMo) in the drug discovery workflow, while demonstrating its systems’ performance in real-world pharma applications.

It’s part of a broader strategy of deploying capital into AI-first companies that can both benefit from and validate Nvidia’s ecosystem, accelerating adoption across industries.

Here are the top ten institutional investors in Recursion Pharmaceuticals (RXRX), based on the most recently reported 13F filings (as of March 31, 2025) and aggregated data sources Yahoo Finance+12:

🏦 Top 10 Institutional Holders of RXRX

Ranked by percentage ownership:

ARK Investment Management LLC — 8.66% (~34.8M shares; ~$184 M)
Vanguard Group Inc. — 8.03% (~32.3M shares; ~$171 M)
Lux Ventures IV LP — 7.46% (~30.3M shares; ~$194 M)
1. Baillie Gifford & Co. — 6.07% (~24.4M shares; ~$129 M)
BlackRock Inc. — 5.78% (~23.5M shares; ~$150 M)
SoftBank Group Corp. — 3.61% (~14.7M shares; ~$94 M)
Kinnevik AB (publ) — 3.30% (~13.4M shares; ~$86 M)
State Street Corp. — 3.22% (~13.1M shares; ~$84 M)
Mubadala Investment Co. PJSC — 3.19% (~13.0M shares; ~$83 M)
Novo Holdings A/S — 2.38% (~9.7M shares; ~$62 M)

🧾 Summary Table

Investor	% Ownership	Approx. Shares
ARK Investment Management LLC	8.66%	~34.8 M
Vanguard Group Inc.	8.03%	~32.3 M
Lux Ventures IV LP	7.46%	~30.3 M
Baillie Gifford & Co.	6.07%	~24.4 M
BlackRock Inc.	5.78%	~23.5 M
SoftBank Group Corp.	3.61%	~14.7 M
Kinnevik AB (publ)	3.30%	~13.4 M
State Street Corp.	3.22%	~13.1 M
Mubadala Investment Co. PJSC	3.19%	~13.0 M
Novo Holdings A/S	2.38%	~9.7 M

💡 Key Insights

Institutional investors control around 75% of RXRX's outstanding shares Nasdaq+
ARK and Vanguard are the two largest, with each holding over 8% of the company.
Lux Ventures IV LP—a prominent insider-linked investor—is effectively the third-largest stakeholder at ~7.5%.
Other heavyweights include Baillie Gifford, BlackRock, SoftBank, and sovereign/strategic holders like Mubadala and Novo Holdings.

Here’s a breakdown of the recent moves by institutional investors in RXRX:

📈 Increased Positions (Recent Quarter)

UBS Asset Management Americas (UBS AM) added 4.15M shares (+183.7%) in Q1 2025 (~$22M) MarketBeat+
UBS Group AG boosted its stake by 2.57M shares (+85.4%) (~$13.6M)
According to CapEdge filings (as of July 22, 2025):
- KLP Kapitalforvaltning AS increased by +20% (~61K shares)
- Steel Peak Wealth Management up +21% (~85K shares)
- Prime Capital Investment Advisors boosted by +61% (~30K shares)
- IMC‑Chicago surged +76% (~284K shares)

📉 Reduced or Exited Positions

RA Capital Management, L.P. fully exited its position, selling 7.73M shares (~$41M) in Q1 2025
CapEdge data shows QRG Capital Management reduced its holding by 32% (~19K shares) as of July 21, 2025

🔍 Additional Context

Total institutional inflows over the past 24 months reached significantly more than outflows:
- 83.2M shares purchased (~$550M)
- 18.3M shares sold (~$117M) MarketBeat
- This reflects overall upward interest, but pockets of profit-taking and rotation remain.
Other Q1 fourth-quarter buyers included firms like Brighton Jones, Victory Capital, and Private Advisor Group, while sellers included RA Capital prominently MarketBeatMarketBeat.

✅ Summary

UBS (both global and Americas units) made the largest scale-ups recently.
RA Capital initiated the most substantial reduction, liquidating its entire stake.
Mid-cap managers like KLP, Steel Peak, Prime Capital, and IMC‑Chicago also significantly expanded their RXRX positions.
Some smaller managers, including QRG Capital, reduced or trimmed their positions.
ED Note: We are long RXRX

Friday, June 27, 2025

When the tech "hits the fan" so to speak, who might bid for Cabaletta Bio and their cutting edge technology?

Cabaletta Bio is a compelling acquisition target in a growing niche—cell therapy for autoimmune diseases. Its unique platform, strong early data, and relatively low valuation make it attractive to major players in biotech and pharma, particularly those with an existing CAR-T infrastructure or autoimmune drug pipeline.

CABA is a small but well-capitalized biotech with a pioneering CAR‑T approach for autoimmune diseases, showing promising data. Its next 12–18 months are defining—success in FDA discussions and continued data strength could trigger a meaningful re‑rating or acquisition by larger biotech/pharma. For risk-tolerant investors, it offers speculative upside tied closely to clinical and regulatory catalysts.

Institutional Ownership Overview

Based on recent filings and data summaries:

Institutional ownership ranges from ~53–63% of outstanding shares, with ~42–44 million shares held by institutions (13F data: 42.9 M shares; 62.97% per Investing.com)
Approximately 110–234 institutional investors have held CABA over the past 24 months (Fintel: 234 owners; MarketBeat: 110 active over 2 years)

📋 Top Institutional Shareholders (Equity Only, via 13F / Public Disclosures)

Citadel Advisors LLC – disclosed 4.82 million shares (~5.20%) as of June 20, 2025 (13G filing)
Bain Capital Life Sciences Investors, LLC – holds ~2.76 million shares (~5.17%) as of Mar 31, 2025 T. Rowe Price Investment Management – among top holders at ~8.36% (~4.46 M shares) BlackRock, Inc. – owns ~6.47% (~3.45 M shares)
Adage Capital Partners – holds ~5.69% (~3.03 M shares) The Vanguard Group – around ~5.33% (~2.84 M shares) .
Jennison Associates LLC – ~4.56% (~2.43 M shares)

Other notable asset managers include Commodore Capital, Cormorant Asset Management, Morgan Stanley, Venrock, Sofinnova, Redmile, Perceptive Advisors, and Fred Alger among active participants

Summary Table

Institutional Holder	Stake %	Shares (Approx.)
Citadel Advisors LLC	5.20%	4.82 M
Bain Capital Life Sciences Investors, LLC	5.17%	2.76 M
T. Rowe Price Investment Mgmt	8.36%	~4.5 M
BlackRock, Inc.	6.47%	~3.4 M
Adage Capital Partners	5.69%	~3.0 M
Vanguard Group	5.33%	~2.8 M
Jennison Associates	4.56%	~2.4 M

📝 Key Takeaways

Citadel Advisors is the largest disclosed institutional investor with over 5% ownership via 13G.
Bain, T. Rowe Price, BlackRock, Adage, Vanguard, and Jennison are major long-only holders.
In total, 50+ million shares are under institutional control—a majority of the float.

Smaller funds like Sofinnova, Perceptive, Commodore, Cormorant, Fred Alger, Redmile, etc., also have meaningful stakes and active trading.

Potential Suitors & M&A Landscape

Big biotech firms with existing autoimmune or cell therapy franchises may find Cabaletta attractive:

Roche/Genentech, Bristol‑Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Amgen, Gilead.
These players already have CAR-T platforms or autoimmunity portfolios and could accelerate CABA’s path to commercialization via acquisition or a licensing deal following pivotal data or FDA alignment.
A successful BLA in myositis could significantly increase attractiveness in M&A.

✅ Key Catalysts to Watch

FDA meetings for registrational cohort alignment (mid-to-late-2025).
Data readouts from SLE, SSc, myositis cohorts at upcoming medical meetings.
BLA filing in myositis, expected 2027.
Potential partnerships or M&A following strong clinical/regulatory momentum.

🧭 Investor Takeaway

High-risk, high-reward: CABA remains speculative until regulatory approvals or acquisition materialize.
Cash runway good through 2026, but watch future dilution/redemptions.
Institutional support strong, but recent sell-offs suggest caution and profit-taking.
M&A potential is strong if critical data milestones are met, making it a high-beta biotech micro-cap.
Best suited for investors with tolerance for biotech volatility and an eye on upcoming newsflows.

📅 Timeline Summary

Event	Expected Timing
FDA alignment — myositis registrational	Mid–2025
SLE/LN registrational discussions	Q3 2025
SSc registrational discussions	Q4 2025
gMG registrational discussions	1H 2026
Myositis BLA submission	2027
Key data updates from RESET trials	Throughout 2025

June 2025 Stock Offering - Institutional buyers in at $2

The June ~12, 2025 underwritten public offering of Cabaletta Bio (ticker: CABA) at a combined unit price of $2.00 ($1.99999 for pre-funded warrants) triggered a Schedule 13G filing when institutional investors surpassed the 5% ownership threshold.

Here's who made the move:

📊 Institutional Buyers (via Schedule 13G filed June 20, 2025):

Citadel Advisors LLC (and affiliated entities):
- Common stock held: 4,687,280 shares
- Beneficial ownership: ~5.0% of outstanding shares
- Voting/dispositive power: Shared over these shares
Citadel Securities LLC (market-making arm):
- Common stock held: 131,280 shares
- Beneficial ownership: ~0.1%
- Voting/dispositive power: Shared
Kenneth Griffin (CEO & Founder of Citadel):
- Total beneficial ownership: 4,818,560 shares (~5.2%)
- This reflects his aggregated share with shared voting/dispositive rights

Why This Matters

The ownership threshold exceeded 5% on June 12, 2025, mandating the 13G disclosure The shared voting structure indicates a passive, non-activist stake—no single entity holds sole control.
This move reflects notable institutional backing, enhancing liquidity and signaling confidence in Cabaletta’s capital raise, but does not change Sandy Dahl’s governance control.

TL;DR

Citadel Advisors – ≈4.69 M shares (~5.0%)
Citadel Securities – ≈0.13 M shares (~0.1%)
Kenneth Griffin – ≈4.82 M shares (~5.2%)

All stakes are shared vs. individually controlled, and the disclosure was triggered by crossing the 5% mark post-offering.

Related Articles in 2025:

Autoimmune diseases (MD, Lupus, Mytosis MS and others) are targets for this cutting edge, Bio Tech microcap - CABA!

Will the New developments from Cabaletto Bio (CABA) make it a takeover target? Stay tuned!

We've been buying these smallcap biotech and healthcare stocks this year! Here's why!

Tuesday, May 27, 2025

Cabaletta Bio (CABA) is a microcap stock with a serious pipeline in the Healthcare field, and a possible takeover target. Read on...

Cabaletta Bio Might See a Takeover Offer in the Near Future

Date: May 27, 2025
Ticker: NASDAQ: CABA
Sector: Biotechnology
Market Cap: ~$150M
Current Share Price: ~$1.75

Executive Summary

Cabaletta Bio has rapidly emerged as a key innovator in cell therapies for autoimmune diseases. With promising clinical data, regulatory tailwinds, a strategic manufacturing buildout, and growing institutional interest, the company may soon become a prime takeover candidate. As large pharmaceutical and biotech players intensify their push into immunology and autoimmune markets, Cabaletta’s lead program, rese-cel, positions the company as an attractive bolt-on acquisition for firms seeking late-stage clinical assets with scalable manufacturing platforms.

1. Clinical Breakthroughs: A Deep Pipeline in Autoimmune Therapies

Cabaletta’s lead therapy, resecabtagene autoleucel (rese-cel), is a CD19-targeting CAR-T cell therapy intended to "reset" the immune system in patients with serious autoimmune conditions. Rese-cel has already shown efficacy across multiple indications:

Myositis: RMAT designation received; BLA submission anticipated in 2027.
SLE and Lupus Nephritis: Patients achieved full remission and renal response; all are off immunosuppressants and steroids.
Systemic Sclerosis (SSc): Early patient data show improved skin and lung function.
Myasthenia Gravis (MG) and Multiple Sclerosis (MS): Clinical trials underway; FDA has granted Fast Track status for MS.

Safety Profile: Rese-cel has a highly favorable profile, with >90% of patients experiencing mild (grade 1 or lower) cytokine release syndrome, and no severe neurological toxicity reported.

2. Strategic Manufacturing Partnerships Add Scalability

Cabaletta is not only advancing in the clinic but also ensuring future commercial readiness:

Lonza Agreement: Expanded clinical manufacturing capabilities.
Cellares Partnership: Successfully validated automated manufacturing of rese-cel using the Cell Shuttle™ platform. This makes the production of CAR-T therapies more scalable and cost-effective—an attractive feature for potential acquirers.

3. Strong Institutional Confidence

Vanguard, Prudential Financial, and Walleye Capital significantly increased their stakes in late 2024 and early 2025.
Such heavyweights rarely invest in micro-cap biotech without seeing long-term upside or M&A potential.
Despite reduced holdings by Fred Alger Management, overall institutional sentiment remains bullish.

4. Upcoming Catalysts That May Trigger Acquisition Interest

June 2025: Key clinical results to be presented at the EULAR Congress.
H2 2025: FDA meetings to discuss registrational trials in SLE, LN, and SSc.
2027: Target BLA submission for rese-cel in myositis—a potentially pivotal milestone that accelerates valuation.

These catalysts, if positive, could pressure potential buyers to move early, while CABA remains undervalued.

5. Financial Position: Runway Through 1H 2026

Cash on hand (as of Dec 2024): $164M
This provides ample time for clinical execution without dilution, enhancing the appeal to potential acquirers.

6. Why a Takeover May Be Imminent

Cabaletta’s profile aligns with key acquisition criteria:

Late-stage lead asset with early regulatory designations (RMAT, Fast Track).
Broad multi-indication applicability across lucrative autoimmune markets.
Scalable and automated manufacturing platforms.
Positive early safety and efficacy data across several trials.
Institutional backing from long-term investors.
A depressed market valuation, with shares down ~85% from peak levels.

Potential Suitors:
Large immunology players and gene/cell therapy leaders like:

Gilead Sciences (Kite)
Roche/Genentech
Bristol-Myers Squibb
Sanofi or Novartis (expanding in CAR-T and autoimmunity)

Valuation Snapshot

Metric	Value (Approx)
Market Cap	$150M
Cash Position	$164M
52-Week High	$13.50
Current Price (May 27, 2025)	~$1.75
Analyst Avg. Target Price	$20.08
Price/Book Ratio	<1 (undervalued)

Conclusion: A Compelling Acquisition Target

Cabaletta Bio stands at the intersection of scientific innovation and unmet medical need. Its autoimmune-focused CAR-T program, strong safety/efficacy signals, and scalable production model present an ideal acquisition case. With near-term catalysts approaching and larger biopharma players under pressure to replenish pipelines, a takeover offer could materialize in the near future.

Investment Outlook: Speculative Buy with Acquisition Upside

Related posts:

Been adding to CABA Bio stock this month. Here's why!

Cures for autoimmune diseases such as MD, Lupus, Mytosis MS and others are targets for this cutting edge, Bio Tech microcap!

We've been collecting these smallcap biotech and healthcare stocks ib 2025! Here's why!

Friday, March 7, 2025

What's up with UiPath, it's Robotics Automation and it's recent push into healthcare?

Below is a comprehensive investment and business report on UiPath

$N Y S E : P A T H$

Please note that all figures and information are based on publicly available data as of the most recent disclosures; for the most up-to-date figures, consult UiPath’s SEC filings, official press releases, and reputable financial news outlets.

1. Company Overview

UiPath is a leading enterprise automation software company, specializing in Robotic Process Automation (RPA), AI-driven document understanding, and, more recently, “agentic automation.” Founded in 2005 in Romania, UiPath has since expanded globally, serving a wide range of industries. The company went public on the New York Stock Exchange in April 2021 under the ticker PATH.

Core Value Proposition

Provides automation solutions (software “robots”) that mimic human actions for repetitive digital tasks.
Integrates AI/ML to enable more complex workflows, including document understanding, natural language processing, and generative AI.
Offers an end-to-end platform for discovery, building, managing, running, and engaging with automation solutions at scale.

2. Recent Developments & Strategic Highlights

2.1 New Global Consulting Agreement with a Major EMR Platform

Announcement (2025): UiPath negotiated a global consulting agreement with a major Electronic Medical Records (EMR) platform to accelerate professional services for healthcare organizations in 16 new countries (e.g., Australia, France, Germany, Italy, Singapore, Sweden, etc.).
Impact:
- Increases UiPath’s global footprint, particularly in the healthcare vertical—a large, growing market.
- Shortens the access and implementation timelines for clients (from weeks to days).
- Reinforces UiPath’s positioning in agentic automation—using large language models (LLMs) and generative AI (GenAI) for autonomous workflows in complex, regulated environments such as healthcare.

2.2 Expansion into “Agentic AI” and Generative AI

UiPath is emphasizing “agentic” automation—where software agents can perceive, reason, and take actions autonomously.
Aligns with the broader enterprise AI trend, positioning UiPath as more than just an RPA vendor.

2.3 Other Key Partnerships & Contracts

Microsoft Collaboration: Integration with Microsoft Power Platform, Azure ML, and other Azure AI services to enhance cross-platform automation.
AWS Partnership: UiPath robots running on AWS to serve large enterprise customers.
SAP Endorsed App: UiPath is an SAP Endorsed App, which helps it sell automation solutions more effectively into the SAP install base.
ServiceNow & Salesforce Integrations: Bolstering UiPath’s ability to automate workflows involving customer service and CRM data.

3. Financial Performance

Note: Figures below are approximate and for illustrative purposes, based on the latest reported fiscal year or quarterly release. Always check the most recent 10-Q/10-K for updated data.

3.1 Revenue & Growth

Revenue: UiPath reported revenues in the range of $1.0–$1.1 billion on an annualized basis in its recent filings. Growth rates have varied quarter to quarter but have typically shown double-digit percentages year-over-year.
Annualized Renewal Run-Rate (ARR): Often cited by UiPath as a key metric, has shown steady increases, reflecting strong customer retention and expansions.

3.2 Profitability & Margins

Gross Margins: Typically strong for software companies (70%–80%+). UiPath reinvests heavily in R&D and market expansion, so operating margins can fluctuate.
Net Income: UiPath has posted occasional net losses, reflecting investment in sales, marketing, and acquisitions. The company has signaled a path toward improved profitability through cost optimization and efficiencies in its go-to-market strategy.

3.3 Cash Position & Balance Sheet

UiPath had a strong cash and short-term investments position, historically in the range of $1.5–$2.0 billion. This ample liquidity provides flexibility to fund R&D, potential acquisitions, and global expansion.
Low debt levels relative to its cash reserves, which generally de-risks the balance sheet.

4. Institutional Investors & Ownership

UiPath’s major institutional investors have included:

ARK Investment Management (Cathie Wood)
BlackRock, Inc.
Morgan Stanley
Vanguard Group

These institutions often rebalance their positions based on market conditions and investment theses; consult the latest 13F filings to see current stakes.

5. Key Customers & Industry Verticals

5.1 Enterprise & Mid-Market Customers

UiPath has historically attracted Global 2000 companies, with a strong presence in financial services, telecom, and manufacturing.
The healthcare sector is becoming a key target, especially with the recent EMR agreement.

5.2 Notable Clients

Large banks (e.g., JP Morgan, Bank of America—though specifics may vary by deployment).
Healthcare organizations (e.g., major hospital systems using UiPath for claims processing, patient data management).
Manufacturing and logistics firms deploying UiPath for supply chain and back-office automation.
Government agencies in various regions for document processing and compliance workflows.

6. Growth Drivers & Prospects

6.1 Continuing Global RPA Adoption

The RPA market is projected to grow in the mid-to-high double digits annually over the next few years. Enterprises continue to automate back-office tasks, fueling demand for UiPath’s core offerings.

6.2 AI & “Agentic” Automation

There is a shift from simple task automation to intelligent, end-to-end workflows leveraging machine learning (ML) and generative AI.
UiPath’s AI Center and new emphasis on “agentic automation” could differentiate it from competitors, attracting enterprise clients looking for advanced, autonomous solutions.

6.3 Industry-Specific Solutions

Verticals like healthcare, financial services, and public sector present large growth opportunities.
The new EMR agreement opens additional healthcare markets—16 new countries—for professional services and automation deployments.

6.4 Ecosystem & Integration

Partnerships with SAP, ServiceNow, Salesforce, Microsoft, and Amazon Web Services expand UiPath’s ecosystem.
Pre-built integrations reduce friction for customers adopting UiPath’s automation platform.

7. Competitive Landscape

Automation Anywhere
- A direct RPA competitor with a cloud-native platform.
- Similar enterprise focus but historically smaller than UiPath in overall market share.
Blue Prism (now part of SS&C)
- Another RPA pioneer, strong in Europe.
- More traditional approach to RPA, though it is now integrating AI components post-acquisition by SS&C.
Microsoft Power Automate
- Part of the Microsoft ecosystem.
- Less feature-rich in pure-play RPA than UiPath, but deeply integrated with Office 365 and other Microsoft products, making it a formidable competitor for some SMB and mid-market use cases.
Appian
- Offers a low-code platform with automation features.
- Focuses on end-to-end process automation, including business process management and RPA.
IBM / Oracle / Salesforce
- Large enterprise software vendors offering automation modules that can overlap with certain UiPath capabilities.
- Typically bigger product portfolios but not purely focused on RPA/automation.

8. Opportunities & Risks

8.1 Opportunities

Healthcare Expansion: The new EMR consulting agreement could catalyze growth in a massive global healthcare market.
AI & Generative Automation: Being at the forefront of agentic AI could differentiate UiPath, opening up new enterprise deals that go beyond standard RPA.
Cross-Selling & Upselling: Existing RPA clients can be sold additional AI modules, document understanding, or expanded service engagements.

8.2 Risks

Competition: The market is crowded. Tech giants and other specialized RPA/AI vendors challenge UiPath’s pricing and market share.
Economic Slowdowns: Enterprise software budgets can contract if macro conditions worsen, potentially delaying automation projects.
Integration & Complexity: As automation and AI become more intertwined, implementation complexity could rise. Companies may opt for simpler, lower-cost solutions if UiPath’s platform is perceived as too costly or complex.
Regulatory / Data Privacy: In healthcare and finance, privacy regulations are stringent, requiring robust compliance frameworks.

9. Conclusion & Investment Perspective

Overall, UiPath (PATH) stands out as a leader in the enterprise automation and AI space. Its:

Strong balance sheet and ample cash provide flexibility.
Healthcare expansion via the global EMR agreement showcases sector-specific growth potential.
Increasing focus on AI (“agentic automation”) aligns UiPath with cutting-edge automation trends and enterprise demand.

For long-term investors who believe in the sustained growth of enterprise automation and AI, UiPath’s combination of market leadership, large addressable market, and evolving AI-driven product strategy presents an attractive thesis. However, potential investors should monitor:

Quarterly execution (ARR, net new customers, partner expansions).
Competition from tech giants and specialized RPA vendors.
Path to profitability, as the company continues to balance growth with controlling costs.

Disclaimer: This report is for informational purposes only and does not constitute financial or investment advice. Always conduct your own due diligence and consult a qualified financial advisor before making any investment decisions.

Ed Note:

We are long UiPath stock!

References & Additional Resources

UiPath SEC Filings (10-Q, 10-K) and Investor Relations: https://www.uipath.com/investors
Company Press Releases: https://www.uipath.com/newsroom
Analyst Reports (e.g., Morgan Stanley, JPMorgan)
Publicly Available Financial Data (e.g., Yahoo Finance, Seeking Alpha, Bloomberg)